Physician profile
John Schaberg
NPI 1851321541
$10,109.07
in general payments reported to CMS, 2019-2025
40 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $131 · 2021: $1,050 · 2022: $1,518 · 2023: $1,941 · 2024: $2,007 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,128 · Education: $74.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,128.02 |
| Education | $74.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,248.22 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,240.94 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $885.56 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $518.81 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $488.01 | 2019-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $413.86 | 2022-2025 | Ibsrela |
| Celgene Corporation | $377.90 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $352.50 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $251.99 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $215.83 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $214.40 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $196.59 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $193.24 | 2025 | Dupixent |
| Boston Scientific Corporation | $160.35 | 2021-2024 | Exalt Model D, Advanix Biliary |
| Ferring Pharmaceuticals INC. | $146.93 | 2021-2025 | Rebyota, Clenpiq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $139.09 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $130.70 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $93.76 | 2020-2023 | Linzess |
| Lilly USA, LLC | $92.78 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $84.28 | 2023-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $80.71 | 2023-2024 | Idacio |
| Celltrion USA INC. | $74.63 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $74.17 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $58.27 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $52.69 | 2025 | Iqirvo |
| Amgen INC. | $52.03 | 2022-2023 | Avsola, Amjevita |
| Organon LLC | $48.01 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $38.37 | 2021-2022 | |
| Alfasigma USA, INC. | $20.65 | 2022 | |
| W. L. Gore & Associates, INC. | $20.54 | 2022 | |
| Mylan Institutional INC. | $18.79 | 2023 | Hulio |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2022 | |
| Novo Nordisk INC | $16.87 | 2025 | Wegovy |
| Redhill Biopharma INC. | $16.09 | 2021 | |
| Ethicon US, LLC | $15.42 | 2021 | |
| Ucb, INC. | $15.14 | 2019 | |
| Shionogi INC | $13.06 | 2019 | |
| Allergan, INC. | $12.53 | 2020 | |
| Vivus LLC | $12.44 | 2021 | |
| Romark Laboratories, Lc | $5.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schaberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.